Current advances in stem cells derived insulin-producing cells for diabetes mellitus therapy

doi:10.3877/cma.j.issn.2095-1221.2023.06.005

Abstract

Abstract:

Diabetes mellitus is a metabolic disease caused by an absolute or relative deficiency in insulin secretion, resulting in high hyperglycemia. Pancreatic β cells are the only cells in the body that secrete insulin, and β cell replacement or supplementation therapy is the fundamental approach for treating diabetes. Inducing stem cell differentiation into insulin-secreting cells (IPCs) through biotechnology can produce insulin for β cell replacement therapy and bring hope for diabetes treatment. However, in stem cell differentiation into IPCs for diabetes treatment, there are still issues such as immature functionality of β cells derived from stem cells, biologic safety and reliability of treatment, and transplant rejection. This article summarizes different sources of stem- induced differentiation into IPCs, other induction protocols, current progress in clinical research, and the existing problems and solutions, with the hope of providing reference for researchers studying methods of IPCs therapy for diabetes.

Key words: Diabetes mellitus, Stem cells, Insulin producing cells, Induction protocols

Ting Yan, Yaoyao Liang, Jin Chen. Current advances in stem cells derived insulin-producing cells for diabetes mellitus therapy[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(06): 355-362.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2023.06.005

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2023/V13/I06/355

Figures/Tables 4

References 72

1	Silva I B B, Kimura C H, Colantoni VP, et al. Stem cells differentiation into insulin-producing cells (IPCs): recent advances and current challenges[J]. Stem Cell Research & Therapy, 2022, 13(1): 309.
2	Han EX, Wang J, Kural M, et al. Development of a bioartificial vascular pancreas[J]. J Tissue Eng, 2021, 12: 20417314211027714.doi:10.1177/20417314211027714.
3	Brusko TM, Russ HA, Stabler CL. Strategies for durable β cell replacement in type 1 diabetes[J]. Science, 2021, 373(6554): 516-522.
4	Pagliuca FW, Millman JR, Gürtler M, et al. Generation of functional human pancreatic β cells in vitro[J]. Cell, 2014, 159(2): 428-439.
5	Rezania A, Bruin J E, Arora P, et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells[J]. Nat Biotechnol, 2014, 32(11): 1121-1133.
6	Ghazizadeh Z, Kao D-I, Amin S, et al. ROCKII inhibition promotes the maturation of human pancreatic beta-like cells[J]. Nat Commun, 2017, 8(1): 298. doi:10.1038/s41467-017-00129-y.
7	杨玉伟，李万里，陈继冰等. 间充质干细胞包裹人胰岛减轻即刻经血液介导的炎症反应的体外研究 [J]. 器官移植, 2023, 14 (4): 562-569.
8	Bourgeois S, Sawatani T, Van Mulders A, et al. Towards a functional cure for diabetes using stem cell-derived beta cells: are we there yet?[J]. Cells, 2021, 10(1): 191. doi:10.3390/cells10010191.
9	Ma X, Lu Y, Zhou Z, et al. Human expandable pancreatic progenitor-derived β cells ameliorate diabetes[J]. Sci Adv, 2022, 8(8): eabk1826.doi:10.1126/sciadv.abk1826.
10	Velazco-Cruz L, Song J, Maxwell KG, et al. Acquisition of dynamic function in human stem cell-derived β cells[J]. Stem Cell Reports, 2019, 12(2): 351-365.
11	Helman A, Cangelosi AL, Davis JC, et al. A nutrient-sensing transition at birth triggers glucose-responsive insulin secretion[J]. Cell Metab, 2020, 31(5): 1004-1016.e5.
12	Nair GG, Liu JS, Russ HA, et al. Recapitulating endocrine cell clustering in culture promotes maturation of human stem-cell-derived β cells[J]. Nat Cell Biol, 2019, 21(2): 263-274.
13	Veres A, Faust AL, Bushnell HL, et al. Charting cellular identity during human in vitro β-cell differentiation[J]. Nature, 2019, 569(7756): 368-373.
14	Hogrebe NJ, Augsornworawat P, Maxwell KG, et al. Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells[J]. Nat Biotechnol, 2020, 38(4): 460-470.
15	Augsornworawat P, Maxwell KG, Velazco-Cruz L, et al. Single-cell transcriptome profiling reveals β cell maturation in stem cell-derived islets after transplantation[J]. Cell Rep, 2020, 32(8): 108067. doi: 10.1016/j.celrep.2020.108067.
16	Guan J, Wang G, Wang J, et al. Chemical reprogramming of human somatic cells to pluripotent stem cells[J]. Nature, 2022, 605(7909): 325-331.
17	Du S, Li Y, Geng Z, et al. Engineering islets from stem cells: the optimal solution for the treatment of diabetes?[J]. Front Immunol, 2022, 13: 869514. doi: 10.3389/fimmu.2022.869514.
18	Yoshihara E, O'Connor C, Gasser E, et al. Immune-evasive human islet-like organoids ameliorate diabetes[J]. Nature, 2020, 586(7830): 606-611.
19	Liuyang S, Wang G, Wang Y, et al. Highly efficient and rapid generation of human pluripotent stem cells by chemical reprogramming[J]. Cell Stem Cell, 2023, 30(4): 450-459.e9.
20	Hosseini SR, Hashemi-Najafabadi S, Bagheri F. Differentiation of the mesenchymal stem cells to pancreatic β-like cells in alginate/trimethyl chitosan/alginate microcapsules[J]. Prog Biomater, 2022, 11(3):273-280.
21	Kawada-Horitani E, Kita S, Okita T, et al. Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade[J]. Diabetologia, 2022, 65(7): 1185-1197.
22	Dai P, Qi G, Xu H, et al. Reprogramming adipose mesenchymal stem cells into islet β-cells for the treatment of canine diabetes mellitus[J]. Stem Cell Research & Therapy, 2022, 13(1): 370.
23	Zhang Y, Gao S, Liang K, et al. Exendin-4 gene modification and microscaffold encapsulation promote self-persistence and antidiabetic activity of MSCs[J]. Sci Adv, 2021, 7(27): eabi4379. doi: 10.1126/sciadv.abi4379.
24	Xiang E, Han B, Zhang Q, et al. Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis[J]. Stem Cell Res Ther, 2020, 11(1): 336. doi: 10.1186/s13287-020-01852-y.
25	Park YM, Yang CM, Cho HY. Therapeutic effects of insulin-producing human umbilical cord-derived mesenchymal stem cells in a type 1 diabetes mouse model[J]. Int J Mol Sci, 2022, 23(13): 6877. doi: 10.3390/ijms23136877.
26	Aly RM, Aglan HA, Eldeen GN, et al. Efficient generation of functional pancreatic β cells from dental-derived stem cells via laminin-induced differentiation[J]. J Genet Eng Biotechnol 2022, 20(1): 85. doi: 10.1186/s43141-022-00369-6.
27	Mamidi A, Prawiro C, Seymour PA, et al. Mechanosignalling via integrins directs fate decisions of pancreatic progenitors[J]. Nature, 2018, 564(7734): 114-118.
28	Maloy MH, Ferrer MA, Parashurama N. In vivo differentiation of stem cell-derived human pancreatic progenitors to treat type 1 diabetes[J]. Stem Cell Rev Rep, 2020, 16(6):1139-1155.
29	Qadir MMF, Álvarez-Cubela S, Klein D, et al. P2RY1/ALK3-expressing cells within the adult human exocrine pancreas are BMP- 7 expandable and exhibit progenitor-like characteristics[J]. Cell Rep, 2018, 22(9):2408-2420.
30	Lammert E, Cleaver O, Melton D. Role of endothelial cells in early pancreas and liver development[J]. Mech Dev, 2003, 120(1): 59-64.
31	Zaret KS. From endoderm to liver bud: paradigms of cell type specification and tissue morphogenesis[J]. Curr Top Dev Biol, 2016, 117: 647-669.
32	Michalopoulos GK. Hepatostat: Liver regeneration and normal liver tissue maintenance[J]. Hepatology, 2017, 65(4):1384-1392.
33	Sarkar S, Munshi C, Chatterjee S, et al. Vector-free in vivo trans-determination of adult hepatic stem cells to insulin-producing cells[J]. Mol Biol Rep, 2019, 46(5): 5501-5509.
34	Ma S, Yang M, Zhou W, et al. An efficient and footprint-free protocol for the transdifferentiation of hepatocytes into insulin-producing cells with IVT mRNAs[J]. Front Genet, 2020, 11: 575. doi: 10.3389/fgene.2020.00575.
35	Hojjat A, Mansour RN, Enderami SE, et al. The differentiation and generation of glucose-sensitive beta like-cells from menstrual blood-derived stem cells using an optimized differentiation medium with platelet-rich plasma (PRP)[J]. Acta Histochem, 2023, 125(3): 152025.doi: 10.1016/j.acthis.2023.152025.
36	Fontcuberta-PiSunyer M, García-Alamán A, Prades È, et al. Direct reprogramming of human fibroblasts into insulin-producing cells using transcription factors[J]. Commun Biol, 2023, 6(1): 256. doi: 10.1038/s42003-023-04627-2.
37	Yagihashi S. Gut as a source of new β-cells and Segi's cap[J]. J Diabetes Investig, 2023: jdi.14025.
38	Guo P, Zhang T, Lu A, et al. Specific reprogramming of alpha cells to insulin-producing cells by short glucagon promoter-driven Pdx1 and MafA[J]. Mol Ther Methods Clin Dev, 2023, 28: 355-365.
39	Huang X, Gu W, Zhang J, et al. Stomach-derived human insulin-secreting organoids restore glucose homeostasis[J]. Nat Cell Biol, 2023, 25:778-786.
40	Nijhoff MF, De Koning EJP. Artificial pancreas or novel beta-cell replacement therapies: a race for optimal glycemic control?[J]. Curr Diab Rep, 2018, 18(11): 110. doi: 10.1007/s11892-018-1073-6.
41	Han L, He H, Yang Y, et al. Distinctive clinical and pathologic features of immature teratomas arising from induced pluripotent stem cell-derived beta cell injection in a diabetes patient[J]. Stem Cells Dev, 2022, 31(5-6): 97-101.
42	Du Y, Liang Z, Wang S, et al. Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates[J]. Nat Med, 2022, 28(2): 272-282.
43	Naji A, Eitoku M, Favier B, et al. Biological functions of mesenchymal stem cells and clinical implications[J]. Cell Mol Life Sci, 2019, 76(17): 3323-3348.
44	Gao S, Zhang Y, Liang K, et al. Mesenchymal stem cells (MSCs): a novel therapy for type 2 diabetes[J]. Stem Cells Int, 2022, 2022: 8637493. doi: 10.1155/2022/8637493.
45	Wruck W, Graffmann N, Spitzhorn L-S, et al. Human induced pluripotent stem cell-derived mesenchymal stem cells acquire rejuvenation and reduced heterogeneity[J]. Front Cell Dev Biol, 2021, 9: 717772.
46	高原，盛伟，黄国英.多能干细胞在体外心脏模型构建研究中的应用[J].中华细胞与干细胞杂志（电子版）,2022,12(5):314-318.
47	Nihad M, Shenoy PS, Bose B. Cell therapy research for diabetes: pancreatic β cell differentiation from pluripotent stem cells[J]. Diabetes Res Clin Pract, 2021, 181: 109084. doi: 10.1016/j.diabres.2021.109084.
48	Balboa D, Barsby T, Lithovius V, et al. Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells[J]. Nat Biotechnol, 2022, 40(7): 1042-1055.
49	Maxwell KG, Augsornworawat P, Velazco-Cruz L, et al. Gene-edited human stem cell–derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice[J]. Sci Transl Med, 2020, 12(540): eaax9106. doi: 10.1126/scitranslmed.aax9106.
50	Augsornworawat P, Velazco-Cruz L, Song J, et al. A hydrogel platform for in vitro three dimensional assembly of human stem cell-derived islet cells and endothelial cells[J]. Acta Biomater, 2019, 97: 272-280.
51	Schulz TC, Young HY, Agulnick AD, et al. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells[J]. PLoS ONE, 2012, 7(5): e37004. doi: 10.1371/journal.pone.0037004.
52	Kharat A, Sanap A, Kheur S, et al. Insulin-producing cell clusters derived from human gingival mesenchymal stem cells as a model for diabetes research[J]. Mol Biol Rep, 2022, 49(12): 11973-11982.
53	Tao T, Wang Y, Chen W, et al. Engineering human islet organoids from iPSCs using an organ-on-chip platform[J]. Lab Chip, 2019, 19(6): 948-958.
54	Xu Y, Huang Y, Guo Y, et al. microRNA-690 regulates induced pluripotent stem cells (iPSCs) differentiation into insulin-producing cells by targeting Sox9[J]. Stem Cell Res Ther, 2019, 10(1): 59. doi: 10.1186/s13287-019-1154-8.
55	Li N, Jiang D, He Q, et al. microRNA-181c-5p promotes the formation of insulin-producing cells from human induced pluripotent stem cells by targeting smad7 and TGIF2[J]. Cell Death Dis, 2020, 11(6): 462. doi: 10.1038/s41419-020-2668-9.
56	Bai C, Li X, Gao Y, et al. Role of microRNA-21 in the formation of insulin-producing cells from pancreatic progenitor cells[J]. Biochim Biophys Acta, 2016, 1859(2): 280-293.
57	Bai C, Gao Y, Zhang X, et al. MicroRNA-34c acts as a bidirectional switch in the maturation of insulin-producing cells derived from mesenchymal stem cells[J]. Oncotarget, 2017, 8(63): 106844-106857.
58	Fernandes F, Kotharkar P, Chakravorty A, et al. Nanocarrier mediated siRNA delivery targeting stem cell differentiation[J]. Current Stem Cell Res Ther, 2020, 15(2): 155-172.
59	Choi J, Shin E, Lee J, et al. Light-stimulated insulin secretion from pancreatic islet-like organoids derived from human pluripotent stem cells[J]. Mol Ther, 2023, 31(5):1480-1495.
60	Xu H, Wang B, Ono M, et al. Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility[J]. Cell Stem Cell, 2019, 24(4): 566-578.e7.
61	Doudna JA. The promise and challenge of therapeutic genome editing[J]. Nature, 2020, 578(7794): 229-236.
62	Svendsen B, Larsen O, Gabe MBN, et al. Insulin secretion depends on intra-islet glucagon signaling[J]. Cell Rep, 2018, 25(5): 1127-1134.e2.
63	Svendsen B, Holst JJ. Paracrine regulation of somatostatin secretion by insulin and glucagon in mouse pancreatic islets[J]. Diabetologia, 2021, 64(1): 142-151.
64	Bruin JE, Asadi A, Fox JK, et al. Accelerated maturation of human stem cell-derived pancreatic progenitor cells into insulin-secreting cells in immunodeficient rats relative to mice[J]. Stem Cell Reports, 2015, 5(6): 1081-1096.
65	Liang Z, Sun D, Lu S, et al. Implantation underneath the abdominal anterior rectus sheath enables effective and functional engraftment of stem-cell-derived islets[J]. Nat Metab, 2023, 5(1): 29-40.
66	Zhang Q, Gonelle-Gispert C, Li Y, et al. Islet encapsulation: new developments for the treatment of type 1 diabetes[J]. Front Immunol, 2022, 13: 869984.
67	Shilleh AH, Russ HA. Cell replacement therapy for type 1 diabetes patients: potential mechanisms leading to stem-cell-derived pancreatic β-cell loss upon transplant[J]. Cells, 2023, 12(5): 698.
68	Oshima M, Pechberty S, Bellini L, et al. Stearoyl CoA desaturase is a gatekeeper that protects human beta cells against lipotoxicity and maintains their identity[J]. Diabetologia, 2020, 63(2): 395-409.
69	Qadir MMF, Álvarez-Cubela S, Belle K, et al. A double fail-safe approach to prevent tumorigenesis and select pancreatic β cells from human embryonic stem cells[J]. Stem Cell Rep, 2019, 12(3): 611-623.
70	Aghazadeh Y, Poon F, Sarangi F, et al. Microvessels support engraftment and functionality of human islets and hESC-derived pancreatic progenitors in diabetes models[J]. Cell Stem Cell, 2021, 28(11): 1936-1949.e8.
71	Powers AC, Brissova M. Microvessels enhance vascularization and function of transplanted insulin-producing cells[J]. Cell Metab, 2021, 33(11): 2103-2105.
72	Helman A, Melton DA. A stem cell approach to cure type 1 diabetes[J]. Cold Spring Harb Perspect Biol, 2021, 13(1): a035741.doi: 10.1101/cshperspect.a035741.

细胞种类	优点	缺点	参考文献
ESCs	具有无限增殖能力的全能干细胞	存在伦理争议，明显的宿主免疫排斥，诱导分化程序复杂、成本高，畸胎瘤形成的风险最高	[4]
iPSCs	可持续的细胞来源，没有伦理争议	重编程效率低，畸胎瘤风险，存活率和植入率低，移植后细胞表型丧失，遗传不稳定，固有免疫原性以及成本高，除杂细胞和规模化生产难	[17,40,41,42]
ASCs	不受伦理问题的限制，致瘤风险较低，数量众多，不存在匹配或免疫排斥问题，具有很强的免疫调节能力	扩增潜力与年龄相关性下降，标准化治疗和大规模培养方面的难题，基因编辑过程中的安全性问题	[1,43,44,45]

细胞种类	优点	缺点	参考文献
ESCs	具有无限增殖能力的全能干细胞	存在伦理争议，明显的宿主免疫排斥，诱导分化程序复杂、成本高，畸胎瘤形成的风险最高	[4]
iPSCs	可持续的细胞来源，没有伦理争议	重编程效率低，畸胎瘤风险，存活率和植入率低，移植后细胞表型丧失，遗传不稳定，固有免疫原性以及成本高，除杂细胞和规模化生产难	[17,40,41,42]
ASCs	不受伦理问题的限制，致瘤风险较低，数量众多，不存在匹配或免疫排斥问题，具有很强的免疫调节能力	扩增潜力与年龄相关性下降，标准化治疗和大规模培养方面的难题，基因编辑过程中的安全性问题	[1,43,44,45]

临床研究注册号	研究名称	研究类型	研究阶段	纳入标准	发起人
NCT04786262	VX-880在1型糖尿病参与者中的安全性、耐受性和有效性研究	是一种研究性同种异体干细胞衍生的、完全分化的、产生胰岛素的胰岛细胞疗法	1，2	持续时间> 5年的1型糖尿病临床病史；在入组前12个月内至少有两次记录的严重低血糖发作；稳定的糖尿病治疗；在筛查前至少3个月持续使用连续血糖监测仪（CGM），并愿意在研究期间使用CGM	Vertex
NCT05791201	VX-264在1型糖尿病参与者中的安全性、耐受性和有效性研究	VX-264同种异体人类干细胞来源的胰岛	1，2	持续时间大于（>） 5年的1型糖尿病临床病史；参与者正在接受稳定的糖尿病治疗；在筛查前至少4周持续使用连续血糖监测（CGM），并愿意在研究期间使用CGM	Vertex
NCT02239354	VC-01™联合产品在1型糖尿病患者中的安全性、耐受性和有效性研究	VC-01™组合产品生物制剂和设备	1，2	男性和女性（非怀孕和非生育能力）；1型糖尿病诊断至少3年；稳定的糖尿病治疗；愿意使用连续血糖仪；可接受的植入候选者	ViaCyte
NCT03162926	VC-02™联合产品在1型糖尿病患者中的安全性和耐受性研究	VC-02组合产品：将PEC-01细胞加载到输送装置中	1	有无生育能力的男性和非孕妇；1型糖尿病诊断至少五（5）年；稳定的糖尿病治疗；愿意使用连续血糖仪；可接受的植入候选者	ViaCyte
NCT02939118	对先前植入VC-01™的受试者进行为期一年的随访安全性研究	观测	1	先前植入VC-01组合产物，随后所有VC-01™单元的植入	ViaCyte
NCT04678557	一项评估VC-01在1型糖尿病患者中的安全性、植入和有效性的研究	VC-01组合产品：PEC-01细胞加载到Encaptra药物递送系统中	1，2	男性和非孕妇；1型糖尿病诊断至少3年；稳定、优化的糖尿病治疗方案；植入和外植体手术的可接受候选者；愿意并能够遵守协议要求；满足每个实验方案的胰岛素剂量要求	ViaCyte
NCT03162926	VC-02™联合产品在1型糖尿病患者中的安全性和耐受性研究	组合产品：VC-02组合产品：将PEC-01细胞加载到输送装置中	1	有无生育能力的男性和非孕妇；1型糖尿病诊断至少五（5）年；稳定的糖尿病治疗；愿意使用连续血糖仪；可接受的植入候选者	ViaCyte
NCT03163511	VC-02™联合产品在1型糖尿病和低血糖无意识受试者中的安全性、耐受性和有效性研究	VC-02组合产品：将PEC-01细胞加载到输送装置中	1，2	男性和非孕妇；1型糖尿病诊断至少五（5）年；低血糖意识不清或显著血糖不稳定；稳定的糖尿病治疗；愿意使用连续血糖仪；可接受的植入候选者	ViaCyte
NCT05210530	一项开放标签的FIH研究，评估VCTX210A组合产品在1型糖尿病受试者中的安全性和耐受性	组合产品：VCTX210A单位CRISPR-Cas9转基因PEC210A细胞加载到递送装置中	1	1型糖尿病诊断至少5年；入组前至少3个月的稳定、优化的糖尿病治疗方案	ViaCyte
NCT05565248	一项开放标签的FIH研究，评估VCTX211联合产品在1型糖尿病受试者中的安全性、耐受性和有效性	组合产品：VCTX211将CRISPR-Cas9转基因PEC211细胞加载到递送装置中	1，2	1型糖尿病诊断至少5年；入组前至少3个月的稳定糖尿病治疗方案	ViaCyte
MR-12-23-017130	自体多能干细胞来源的胰岛样细胞移植治疗1型糖尿病的探索性临床研究	干预性研究	1，2	1型糖尿病（包括已接受肝、肾等器官移植）患者；激发C肽< 0.3ng/mL；近3个月，糖化血红蛋白（HbA1c）7%~ 10%；患者在纳入此项目前12个月内，至少发生过1次严重的低血糖症；能够参与强化血糖管理，依从性较好	天津市第一中心医院

临床研究注册号	研究名称	研究类型	研究阶段	纳入标准	发起人
NCT04786262	VX-880在1型糖尿病参与者中的安全性、耐受性和有效性研究	是一种研究性同种异体干细胞衍生的、完全分化的、产生胰岛素的胰岛细胞疗法	1，2	持续时间> 5年的1型糖尿病临床病史；在入组前12个月内至少有两次记录的严重低血糖发作；稳定的糖尿病治疗；在筛查前至少3个月持续使用连续血糖监测仪（CGM），并愿意在研究期间使用CGM	Vertex
NCT05791201	VX-264在1型糖尿病参与者中的安全性、耐受性和有效性研究	VX-264同种异体人类干细胞来源的胰岛	1，2	持续时间大于（>） 5年的1型糖尿病临床病史；参与者正在接受稳定的糖尿病治疗；在筛查前至少4周持续使用连续血糖监测（CGM），并愿意在研究期间使用CGM	Vertex
NCT02239354	VC-01™联合产品在1型糖尿病患者中的安全性、耐受性和有效性研究	VC-01™组合产品生物制剂和设备	1，2	男性和女性（非怀孕和非生育能力）；1型糖尿病诊断至少3年；稳定的糖尿病治疗；愿意使用连续血糖仪；可接受的植入候选者	ViaCyte
NCT03162926	VC-02™联合产品在1型糖尿病患者中的安全性和耐受性研究	VC-02组合产品：将PEC-01细胞加载到输送装置中	1	有无生育能力的男性和非孕妇；1型糖尿病诊断至少五（5）年；稳定的糖尿病治疗；愿意使用连续血糖仪；可接受的植入候选者	ViaCyte
NCT02939118	对先前植入VC-01™的受试者进行为期一年的随访安全性研究	观测	1	先前植入VC-01组合产物，随后所有VC-01™单元的植入	ViaCyte
NCT04678557	一项评估VC-01在1型糖尿病患者中的安全性、植入和有效性的研究	VC-01组合产品：PEC-01细胞加载到Encaptra药物递送系统中	1，2	男性和非孕妇；1型糖尿病诊断至少3年；稳定、优化的糖尿病治疗方案；植入和外植体手术的可接受候选者；愿意并能够遵守协议要求；满足每个实验方案的胰岛素剂量要求	ViaCyte
NCT03162926	VC-02™联合产品在1型糖尿病患者中的安全性和耐受性研究	组合产品：VC-02组合产品：将PEC-01细胞加载到输送装置中	1	有无生育能力的男性和非孕妇；1型糖尿病诊断至少五（5）年；稳定的糖尿病治疗；愿意使用连续血糖仪；可接受的植入候选者	ViaCyte
NCT03163511	VC-02™联合产品在1型糖尿病和低血糖无意识受试者中的安全性、耐受性和有效性研究	VC-02组合产品：将PEC-01细胞加载到输送装置中	1，2	男性和非孕妇；1型糖尿病诊断至少五（5）年；低血糖意识不清或显著血糖不稳定；稳定的糖尿病治疗；愿意使用连续血糖仪；可接受的植入候选者	ViaCyte
NCT05210530	一项开放标签的FIH研究，评估VCTX210A组合产品在1型糖尿病受试者中的安全性和耐受性	组合产品：VCTX210A单位CRISPR-Cas9转基因PEC210A细胞加载到递送装置中	1	1型糖尿病诊断至少5年；入组前至少3个月的稳定、优化的糖尿病治疗方案	ViaCyte
NCT05565248	一项开放标签的FIH研究，评估VCTX211联合产品在1型糖尿病受试者中的安全性、耐受性和有效性	组合产品：VCTX211将CRISPR-Cas9转基因PEC211细胞加载到递送装置中	1，2	1型糖尿病诊断至少5年；入组前至少3个月的稳定糖尿病治疗方案	ViaCyte
MR-12-23-017130	自体多能干细胞来源的胰岛样细胞移植治疗1型糖尿病的探索性临床研究	干预性研究	1，2	1型糖尿病（包括已接受肝、肾等器官移植）患者；激发C肽< 0.3ng/mL；近3个月，糖化血红蛋白（HbA1c）7%~ 10%；患者在纳入此项目前12个月内，至少发生过1次严重的低血糖症；能够参与强化血糖管理，依从性较好	天津市第一中心医院

[1]	Jinmei He, Lixue Yin, Jing Tan, Wenjun Zhang, Rui Wang, Mei Ren, Mingjiao Liao. Evaluation of potential left ventricular systolic dysfunction in patients with type 2 diabetes mellitus using ultrasonic myocardial work technology [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(10): 1029-1035.
[2]	Jie Wang, Bowen Ding, Jian Yin. Clinical analysis of 52 patients with diabetic mastopathy [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(05): 285-289.
[3]	Yangwenxiang Wei, Haoran Huang, Yuhao Liu, Zhenqiu Chen, Haibin Wang, Chi Zhou. Outlooks and challenges in cell therapy of osteonecrosis of femoral head [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(05): 694-700.
[4]	Linian Han, Jun Wang. Advances in the treatment of radiation-induced skin injury [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(06): 533-537.
[5]	Yuqing Liu, Yongchun Gu, Fanwen Meng, Suping Zhang. Establishment of data independent acquisition quantification proteomic method in dental stem cells [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2024, 18(01): 12-21.
[6]	Shuai Zhao, Wei Wang, Ruiqi Li, Jiajie Zhou, Daorong Wang. Clinical efficacy and influencing factors of 3D laparoscopic sleeve gastrectomy for the treatment of obesity combined with type 2 diabetes mellitus [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(02): 146-149.
[7]	Guangjing Cui, Zhaoguang Wang, Xuemei Zhang, Jiefang Xia, Jialiang Li, Kai Sheng, Guangqiang Ren, Dong Liu. Influence of tissue acquisition location and sample breakage on the quality of placental-derived hematopoietic stem cells [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(06): 331-338.
[8]	Jiaming Fan, Ziying Yang, Zhenhui Feng, Yihuan Chen, Yutong Wang, Zhenya Shen. Analysis of differential miRNA expression related to the efficacy of stem cell transplantation in dilated cardiomyopathy [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(05): 288-298.
[9]	Jianan Huang, Tuoying Jiang, Ke Yao, Luyang Yu, Jinying Li. Advances of amniotic membrane and its derived epithelial stem cells in corneal regenerative medicine [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(05): 299-303.
[10]	Jun Wu, Lixuan Chen, Yang Xiao. Analysis of dual filing research projects on stem cells in China [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(05): 304-309.
[11]	Bingbing Xie, Manting Xie, Qiuling Xiang. Research progress of induced pluripotent stem cells in cell models of hereditary cardiomyopathy [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(05): 315-320.
[12]	Lili Guo, Mou Gao, Ruxiang Xu. Recent progress in the treatment of spinal cord injury [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2023, 09(06): 321-324.
[13]	Zhengying Zhang, Yang Ju, Xiaoning Liu. Effect of oral metformin on postoperative recurrence of type 2 diabetes mellitus with colorectal adenoma [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 485-488.
[14]	Nianyu Xue, Shengmin Zhang, Lingheng Wu, Lei Sha, Lanyue Tong, Cuiqin Shen, Zhaojun Li, Lianfang Du. Effect of serum bilirubin on myocardial function in patients with type 2 diabetes before cardiac structural changes [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(09): 1004-1009.
[15]	Guoxiao Xie, Lingxia Zhao, Xuehua Xue. Application of chronic disease management model in diabetes community management [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 587-590.

Please choose a citation manager

Content to export